News | Proton Therapy | September 25, 2020

100,000 Patients Treated with IBA Proton Therapy Technology

Important milestone demonstrates the unrivaled experience, technological innovation and global market leadership of IBA and its clinical partners

Important milestone demonstrates the unrivalled experience, technological innovation and global market leadership of IBA and its clinical partners

September 25, 2020 — IBA (Ion Beam Applications SA) announced that more than 100,000 patients have now been treated with IBA proton therapy systems around the world. This is an important milestone that marks a step towards IBA’s mission to make proton therapy available to all patients who could benefit from it, by providing healthcare professionals with the most advanced, high performance proton therapy solutions. This milestone is a proud moment for IBA’s employees and clinical partners around the world as they remain united in their efforts to maximize the positive impact on cancer patients’ lives.

Olivier Legrain, Chief Executive Officer at IBA, commented: “We are immensely proud that IBA’s technology has impacted 100,000 lives, giving patients and their families a new hope for the future. Reaching this milestone would not have been possible without the commitment of our employees and the close relationships that we have continued to build with our clients and partners over the last 30 years. Our common goal is to make proton therapy accessible to a greater number of patients, and we believe that our passion, energy and expertise will enable us to achieve this. We continue to pursue further innovation by developing new technologies that will allow us to provide increasingly high standards while reducing treatment costs. I would like to offer my warmest thanks to our partners and employees for their efforts to protect, enhance and save lives.” 

Proton therapy is one of the most promising forms of cancer therapy and is considered the most advanced form of radiotherapy in cancer treatments. Proton therapy makes it possible to target tumors with better precision, minimizing radiation exposure of the surrounding healthy tissue and thereby improving the quality of life of patients during and after treatment.

The clinical benefits of proton therapy are increasingly acknowledged. As the number of patients being treated with proton therapy continues to grow, appreciation of the effectiveness of the technology is also increasing within the medical community. A large number of clinical studies are currently ongoing and their results have the potential to open a new era for proton therapy treatment.

Proton therapy is becoming more and more accessible to a growing number of patients throughout the world. IBA has invested substantial resources in researching and developing new approaches to minimize the cost of proton therapy and make it more accessible to the maximum number of cancer patients. IBA’s Proteus ONE compact single room solution is game changing with regard to making the treatment more accessible, whilst retaining the latest technological capabilities in proton therapy.

IBA continues to invest in the research and development of innovative technological solutions to further advance its proton therapy offering. The technological roadmap of IBA is focused on three areas: Motion Management, Arc Therapy and FLASH Irradiation. IBA constantly looks to improve the proton therapy technology for the benefit of patients, in close collaboration with its customers and industrial partners.

The largest and most experienced proton therapy community. With 36 centers treating patients in 86 rooms, and another 20 centers in development, IBA’s user community is unrivalled. This unique experience from IBA clinical partners coupled with IBA’s unique technological expertise and open partnership philosophy ideally positions the company to continue to lead innovation in proton therapy.

For more information: www.iba-worldwide.com

Related Content

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

News | Radiation Oncology | July 21, 2021
July 23, 2021 — Mevion Medical Systems announced that it has delivered the 15-ton compact accelerator to...
ASTRO just issued the following statement in response to the Radiation Oncology Model update in yesterday's HOPPS proposed rule, which compounds significant and detrimental cuts to the cancer care specialty in the proposed 2022 MPFS

Getty Images

News | Radiation Therapy | July 20, 2021
July 20, 2021 — In response to consecutive weeks of proposed...
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds

(L-R) Associate Professor Peter Brotchie (St Vincent's), Dr Ruwan Tennakoon (RMIT), Professor John Thangarajah (RMIT), Dr Mark Page (St Vincent's). Image courtesy of St Vincent's Hospital Melbourne

News | Prostate Cancer | July 19, 2021
July 19, 2021 — Prostate cancer is the most diagnosed
Ramon Alfredo Siochi, Ph.D. — the director of medical physics at WVU — led a task group to help ensure the accuracy of data that dictates a cancer patient's radiation therapy.

Ramon Alfredo Siochi, director of medical physics at West Virginia University. Image courtesy of WVU Photo/Aira Burkhart

News | Radiation Oncology | July 15, 2021
July 15, 2021 — Just as helicopter traffic reporters use their "bird's eye view" to route drivers around roadblocks s
NeuroLogica joins forces with Massachusetts General Hospital to pilot OmniTom Elite with Photon Counting Detector (PCD) technology at patient point-of-care

NeuroLogica joins forces with Massachusetts General Hospital to pilot OmniTom Elite with Photon Counting Detector (PCD) technology at patient point-of-care. (Photo: Business Wire)

News | Computed Tomography (CT) | July 13, 2021
July 13, 2021 — NeuroLogica Corp.
 The numbers of cancer screening tests rebounded sharply in the last quarter of 2020, following a dramatic decline in the first months of the COVID-19 pandemic, at one large hospital system in the Northeastern United States. These findings were released in a study published in Cancer Cell. The research also found an increase in racial and socioeconomic disparities among users of some screening tests during the pandemic.

Getty Images

News | Radiation Oncology | July 12, 2021
July 12, 2021 — The numbers of...
To help enhance the images and information provided to clinicians for radiation oncology treatment planning, GE Healthcare will integrate Spectronic Medical’s AI-based software with its industry leading AIR Recon DL technology
News | Artificial Intelligence | July 09, 2021
July 9, 2021 — GE Healthcare announced the integration of S...
American Society for Radiation Oncology (ASTRO) to host in-person Annual Meeting in Chicago, October 24-27

Getty Images

News | ASTRO | July 08, 2021
July 8, 2021 — Registration opens today for the American Society for Radiation Oncology's (...